Literature DB >> 7689439

The future of the quinolones.

V T Andriole1.   

Abstract

This review attempts to predict the future of the newer fluoroquinolones by examining what we have learned about this class of compounds during the past decade, as well as what we are currently learning from research and developmental efforts. The molecular mechanism of action of these compounds provides the potential for use in clinical medicine in areas other than their role as antibacterial agents. The newer fluoroquinolones that are currently available and those that have been introduced into the pipeline are categorised by their current stage of development. Also listed are those compounds that have been withdrawn from further investigation. Office practice physicians consider the oral fluoroquinolones to be very effective therapeutic agents for many of their patients. Thus, the future of the fluoroquinolones looks promising because of their unique mechanism of action, the possibility of developing novel and improved compounds in this class, and the acceptance of these compounds as effective therapeutic agents by clinicians.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689439     DOI: 10.2165/00003495-199300453-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  28 in total

1.  Nalidixic acid and bacterial chromosome replication.

Authors:  G C Crumplin; J T Smith
Journal:  Nature       Date:  1976-04-15       Impact factor: 49.962

2.  Clinical isolate of Citrobacter freundii highly resistant to new quinolones.

Authors:  H Aoyama; K Fujimaki; K Sato; T Fujii; M Inoue; K Hirai; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

3.  Mode of incomplete cross-resistance among pipemidic, piromidic, and nalidixic acids.

Authors:  S Inoue; T Ohue; J Yamagishi; S Nakamura; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

4.  In vitro activity of CP-74667 compared with four other fluoroquinolones.

Authors:  R N Jones; M E Erwin
Journal:  Diagn Microbiol Infect Dis       Date:  1992-08       Impact factor: 2.803

Review 5.  Mode of action of the new quinolones: new data.

Authors:  D C Hooper; J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

6.  In vitro activities of five quinolones against Chlamydia pneumoniae.

Authors:  M R Hammerschlag; C L Hyman; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

7.  In vitro activity of OPC-17116.

Authors:  H C Neu; W Fang; J W Gu; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

8.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; T Itoh; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

Review 9.  Use of quinolones in treatment of prostatitis and lower urinary tract infections.

Authors:  V T Andriole
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

10.  Induction of calf thymus topoisomerase II-mediated DNA breakage by the antibacterial isothiazoloquinolones A-65281 and A-65282.

Authors:  W E Kohlbrenner; N Wideburg; D Weigl; A Saldivar; D T Chu
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

View more
  6 in total

1.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

2.  In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  A B Brueggemann; K C Kugler; G V Doern
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

Review 3.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  The future of the quinolones.

Authors:  V T Andriole
Journal:  Drugs       Date:  1999       Impact factor: 9.546

5.  Inhibition of rat parotid gland growth response induced by chronic isoproterenol following treatment with quinolone antibiotics.

Authors:  B Kelentey; M Kerr; Z Tao; K R Purushotham; M G Humphreys-Beher; T Zelles
Journal:  Mol Cell Biochem       Date:  1996-12-06       Impact factor: 3.396

6.  Sequencing of bacterial genomes: principles and insights into pathogenesis and development of antibiotics.

Authors:  Eric S Donkor
Journal:  Genes (Basel)       Date:  2013-10-14       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.